US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

11.42

-0.1900-1.64%

Post-market: 11.420.00000.00%19:57 EDT

Volume:407.86K

Turnover:4.67M

Market Cap:631.01M

PE:9.68

High:11.61

Open:11.61

Low:11.42

Close:11.61

52wk High:13.59

52wk Low:11.42

Shares:55.25M

Float Shares:55.25M

Volume Ratio:1.27

T/O Rate:0.74%

Dividend:1.42

Dividend Rate:12.40%

EPS(TTM):1.18

ROE:--

ROA:--

PB:0.79

PE(LYR):- -

Loading ...

Overview Company News Filings

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Tyler Van Buren Reiterates Buy on Artiva, Citing Strong AlloNK RA Efficacy and Funded Path to Registrational Trial

Press Release: Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Brookfield Real Assets Income Fund announces annual shareholder meeting

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

RUSAL’s Yuan-Denominated Bonds Receive ruA+ Rating from Expert RA

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/RA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":11.42,"timestamp":1791230400000,"preClose":11.61,"halted":0,"volume":407856,"hourTrading":{"tag":"盘后","latestPrice":11.42,"preClose":11.42,"latestTime":"19:57 EDT","volume":208,"amount":2375.58,"timestamp":1791244662180,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.016365202411714,"floatShares":55245934,"shares":55254696,"eps":1.18,"marketStatus":"Not Yet Opened","change":-0.19,"latestTime":"10-05 16:00:00 EDT","open":11.61,"high":11.61,"low":11.415,"amount":4668357.298752,"amplitude":0.016796,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.18,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791273600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":11.61,"dividendRate":0.124037,"preHourTrading":{"tag":"盘前","latestPrice":11.67,"preClose":11.61,"latestTime":"08:43 EDT","volume":26,"amount":303.42,"timestamp":1791204191510,"change":0.06,"changeRate":0.005168,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":11.42,"preClose":11.42,"latestTime":"19:57 EDT","volume":208,"amount":2375.58,"timestamp":1791244662180,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.266624},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.266624,"shares":55254696,"dividePrice":1.4165,"high":11.61,"amplitude":0.016796,"preClose":11.61,"low":11.415,"week52Low":11.415,"pbRate":"0.79","week52High":13.59,"institutionHeld":0,"latestPrice":11.42,"eps":1.18,"divideRate":0.124037,"volume":407856,"delay":0,"ttmEps":1.18,"open":11.61,"prevYearClose":12.96,"prevWeekClose":11.61,"prevMonthClose":11.55,"prevQuarterClose":11.55,"fiveDayClose":11.54,"twentyDayClose":12.51,"sixtyDayClose":12.83},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-12-10","symbol":"RA","amount":0.118,"announcedDate":"2026-09-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-12-10","defaultRemindTime":1796913000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-12-24","payableDate":"2026-12-10","currency":"USD","dateTimestamp":1796878800000,"payDate":"2026-12-24"},{"date":"2026-11-12","symbol":"RA","amount":0.118,"announcedDate":"2026-09-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-11-12","defaultRemindTime":1794493800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-11-27","payableDate":"2026-11-12","currency":"USD","dateTimestamp":1794459600000,"payDate":"2026-11-27"},{"date":"2026-10-09","symbol":"RA","amount":0.118,"announcedDate":"2026-09-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-10-09","defaultRemindTime":1791552600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-23","payableDate":"2026-10-09","currency":"USD","dateTimestamp":1791518400000,"payDate":"2026-10-23"},{"date":"2026-09-10","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-10","defaultRemindTime":1789047000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-24","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1789012800000,"payDate":"2026-09-24"},{"date":"2026-08-06","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-06","defaultRemindTime":1786023000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-20","payableDate":"2026-08-06","currency":"USD","dateTimestamp":1785988800000,"payDate":"2026-08-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635171647","title":"Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2635171647","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635171647?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761800,"startTime":"0","endTime":"0","summary":"Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294940/0/en/Vor-Bio-Announces-Publication-of-Interim-Analysis-of-TELIGAN-a-China-Phase-3-Trial-of-Telitacicept-in-IgA-Nephropathy-in-The-New-England-Journal-of-Medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782088","title":"Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782088","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782088?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initia","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293996/24675/en/Fate-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU0289960550.SGD","BK4139","FATE","IE00BLSP4239.USD","BK4080","LU2347655156.SGD","LU2237443622.USD","LU0170899867.USD","CMC","LU1868836591.USD","LU1221951046.USD","IIM","LU1732799900.SGD","SG9999011175.SGD","LU1894683264.USD","IND","BK4504","LU0882574139.USD","LU0096364046.USD","BK4581","LU2506951875.HKD","SG9999014559.SGD","BK4533","LU0545039389.USD","LU1920062954.HKD","IE00B3PB1722.GBP","LU2237443465.HKD","IE00BBT3K403.USD","RA","LU0795875086.SGD","SG9999014567.USD","IE00BVYPNW00.USD","LU1670711123.USD","LU0971096721.USD","LU2125154935.USD","KO","LU0949170772.SGD","LU0912757837.SGD","LU2133065610.SGD","SITC","CAR","LU1920063259.USD","LU2125154778.USD","LU2746668974.SGD","SLE","LU0098860793.USD","LU1894683348.USD","LU1868837136.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782086","title":"Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782086","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782086?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3294002/0/en/Vor-Bio-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","RA","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634404286","title":"Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2634404286","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634404286?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:00","pubTimestamp":1778500800,"startTime":"0","endTime":"0","summary":"Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF (+27%) and APONVIE (+50%)Q1 2026 total net revenue of $34.7 millionReached settlement with Baxter Healthca","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291812/0/en/Heron-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Reaffirms-Guidance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","CINV","HRTX","RA","BK4139","BK4195","PFS","BK4161","MEC","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634880832","title":"Tyler Van Buren Reiterates Buy on Artiva, Citing Strong AlloNK RA Efficacy and Funded Path to Registrational Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634880832","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634880832?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:55","pubTimestamp":1778496919,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ARTV stock, giving a Buy rating on May 8. Tyler Van Buren has given his Buy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tyler-van-buren-reiterates-buy-on-artiva-citing-strong-allonk-ra-efficacy-and-funded-path-to-registrational-trial-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tyler-van-buren-reiterates-buy-on-artiva-citing-strong-allonk-ra-efficacy-and-funded-path-to-registrational-trial-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1989773731.SGD","BK4139","BK4023","ARTV","BK4585","LU1989763005.USD","TYL","BK4588","RA","LU0390134368.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633943274","title":"Press Release: Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633943274","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633943274?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:31","pubTimestamp":1778236260,"startTime":"0","endTime":"0","summary":"Initial AlloNK  clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis  patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents. AlloNK treatment regimen demonstrated a consistent pattern of deep B-cell depletion and tolerability results supportive of outpatient administration in community rheumatology settings. U.S. Food and Drug Administration  alignment on a single Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients, with ACR50 at six months as the primary endpoint; trial initiation planned for H2 2026. Multiple oral and poster presentations at EULAR 2026, including a late-breaking oral presentation on AlloNK clinical efficacy in refractory RA, Sjgren disease  and systemic sclerosis . autoimmune diseases. The broader autoimmune dataset also included 11","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","ARTV","BK4139","BK4022","BK4232","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633437715","title":"Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633437715","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633437715?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:30","pubTimestamp":1778236200,"startTime":"0","endTime":"0","summary":"Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no pat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/08/3290957/0/en/Artiva-Announces-Positive-Initial-Clinical-Data-with-AlloNK-Across-Multiple-Autoimmune-Diseases-and-FDA-Alignment-to-Initiate-Phase-3-Registrational-Trial-in-Rheumatoid-Arthritis-i.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","IE00B7SZL793.SGD","LU0963586101.USD","BK4006","LABU","RA","IE00B19Z4B17.USD","LU2065731478.USD","CRS","IE00B66KJ199.SGD","IE0031619046.USD","BK4187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145383","title":"Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145383","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145383?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for relap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289800/0/en/Cullinan-Therapeutics-Provides-Corporate-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","RA","BK4139","SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631636287","title":"Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631636287","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631636287?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:00","pubTimestamp":1777546800,"startTime":"0","endTime":"0","summary":"KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to K","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284687/0/en/Kymera-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BP","SID","BK4006","BK4201","PN","LU1829250122.USD","KYMR","BK4132","BK4585","IBD","BK4139","ATS","LU0006061336.USD","AD","LU0162691827.USD","LU0320765646.SGD","RA","BK4161","EASI","BK4588","LU0072461881.USD","BK4096","LU1162221912.USD","BPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627745208","title":"Brookfield Real Assets Income Fund announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627745208","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627745208?lang=en_us&edition=fundamental","pubTime":"2026-04-14 00:41","pubTimestamp":1776098468,"startTime":"0","endTime":"0","summary":"Brookfield Real Assets Income Fund set May 21, 2026, for virtual annual shareholder meeting.Shareholders will vote on election of Class I directors.Board nominees include Brian F. Hurley as interested director, Betty A. Whelchel as independent director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brookfield Real Assets Income Fund Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL3RFkLN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626159983","title":"Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626159983","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626159983?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:00","pubTimestamp":1775779200,"startTime":"0","endTime":"0","summary":"SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. , a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application  for its core product, zemprocitinib capsules, for the treatment of moderate-to-severe atopic dermatitis , has been formally accepted by the Center for Drug Evaluation  of the China National Medical Products Administration . This acceptance marks a critical milestone in the company's clinical development in inflammatory skin diseases and represents an important step toward Lynk Pharmaceuticals' transition to commercialization. Zemprocitinib capsules have the potential to provide a new treatment option for patients with atopic dermatitis.Preclinical and clinical studies have demonstrated that zemprocitinib potently and dose-dependently inhibits multiple JAK1-mediated inflammatory signaling pathways, supporting its therapeutic poten","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lynk-pharmaceuticals-announces-nda-acceptance-for-zemprocitinib-by-nmpa-302738518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","BK4132","CDE.AU","AD","LU1223082196.USD","LU1223082519.USD","LU1223083913.SGD","RA","BK4099","BK7050","ZK","AS","CDE","BK4202"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625732914","title":"RUSAL’s Yuan-Denominated Bonds Receive ruA+ Rating from Expert RA","url":"https://stock-news.laohu8.com/highlight/detail?id=2625732914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625732914?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:19","pubTimestamp":1775639978,"startTime":"0","endTime":"0","summary":"The latest update is out from United Co RUSAL ( ($HK:0486) ). United Company RUSAL has disclosed that its BO-001P-16 series exchange-traded bonds, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rusals-yuan-denominated-bonds-receive-rua-rating-from-expert-ra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rusals-yuan-denominated-bonds-receive-rua-rating-from-expert-ra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":52,"code":"91000000","status":"200"}]}}